Cyprotex Share Discussion Threads

[old crow] 22/11/2010 12:10

Well done buywell, maybe the Crows will add another 83k if he can buy
well under 5p

[buywell2] 22/11/2010 11:24

Lots of talk about developing countries buying UK companies about

We know from the recent poactiveinvestors article that IPGL bought ibn Baxter to add value to Cyprotex with a view to selling the company circa 3 years later.

I think Shanghai ChemPartner Ltd,could be one of those bidding when the time comes..... why ?

1. Because China is buying UK companies and has billions of cash to spend

2. Cyprotex has a LSE stock exchange listingwhich any Chinese company would love

3. Cyprotex has unique own brand software 'LABSYS' for quality control of it's automated processes and each drug sample to be tested

4. Cyprotex now has unique IP and technology after the Apredica and Cellumen purchases

5. Cyprotex now has USA exposure with labs and staff

But I wonder also about the Chinese being possible favorite also through this

[buywell2] 20/11/2010 21:47

Chart looking good

green and black ma's soon will be crossing like in june

Move to 7.5p is then on as long as news is good on wednesday

[buywell2] 20/11/2010 21:41

Market update should be out wednesday

[buywell2] 19/11/2010 07:52

Here is a bit of old news for you to look at and listen to



It gives you a flavor of what Cyprotex do re ADME .... but NOT T (toxicology) , where Cyprotex have recently added a NEW lab to the lab shown in the video.

It does not talk about the Apredica acquisition in the USA ....


A NEW YOU TUBE VIDEO PLEASE ALONG THE LINES OF THIS ONE


WHICH IS ABOUT MY NUMBER 3 CHOICE IN THE HEADER WITH PROACTIVEINVESTORS

Or something along these lines


Cyprotex need to beat their drum and get better PR

A new video would help as would the appointment of someone like this


We are NOT on the radar
why not give these a try

[bobby.ifa] 19/11/2010 07:25

That 16 page pdf was most interesting. Anymore?

[buywell2] 19/11/2010 07:05

Another assay coming soon 'time dependent IC50 shift' expect news any day



see page 1365

extract
'The time-dependent IC50 shift approach (Fig.
5) is another method used in the discovery stage for rigorous comparison
of several lead candidates for nomination of a compound into
development. The data obtained from this method can also be useful
for setting up the concentration range for determination of inactivation
kinetic constants. The IC50 shift method has the capability for simultaneous
detection of both reversible inhibitors and time-dependent
inhibitors, plus the added benefit for potentially predicting drug-drug
interactions'

this folllows on from what I said about the importance of assays that involve drug/drug interactions when Cyprotex first released a cytochrome P450 assay around a year back. Seems to me that clients using the original assay have asked for more assays that give information about drug/drug interactions.

Obviously time in the body ie liver where it is metabolized ..... is a big factor.
So there could soon be yet another £250k a year client added to the growing list.

[buywell2] 18/11/2010 16:08

Market update should be next wednesday I reckon

[cotton4] 18/11/2010 06:58

Jobs now down to team leader only. New scientist taken on. Encouraging.

[old crow] 12/11/2010 09:40

Noted 201k buy @ 4.97p but not the Crows this time
but could buying for 5p be soon gone for ever.

[buywell2] 09/11/2010 09:43

And that was

Director/PDMR Shareholding



TIDMCRX

RNS Number : 8198V
Cyprotex PLC
08 November 2010

8 November 2010

Cyprotex PLC
("Cyprotex" or the "Company")

Director dealings

Macclesfield, UK - Cyprotex PLC (LSE: CRX), the preclinical ADME Tox services
company, was informed on 21 October 2010 that Ralph Stephen Harris transferred
707,142 ordinary shares of 0.1 pence each out of his total holding of 1,507,142
in the Company ("Ordinary Shares") to his IPS Partnership SIPP. Mr. Harris's
beneficial holding remains unchanged at 0.67%of the total issued share capital
of the Company.

[spekky] 08/11/2010 17:18

I see we have official confirmation of what I thought in post 38.

[buywell2] 08/11/2010 09:52

Not much to say now till the next market update which should be either this wed or next wed if the last two years updates follow on

That should supply info to discuss in more depth

Should be positive news I believe, so this could be a buying opportunity sub 5p

If it is good news then 5p might never be seen again

DYOR

[old crow] 06/11/2010 16:11

buywell and all, keep it flowing.

[redprince] 02/11/2010 08:40

Nice synergy.

[buywell2] 02/11/2010 05:59

Remember , when Cyprotex bought Apredica for £2.6m , it also got Cellumen as well. ( click on website links in the header for conformation )

Cellumen was bought by Apredica days before Cyprotex bought Apredica, so Baxter effectively craftily got two companies for £2.6m.

How much was Cellumen worth ?

Tony Baxter, CEO of Cyprotex, told BioWorld International it was "a bit of a surprise" to have the opportunity to acquire Cellumen, which has raised $12 million in venture capital funding since it was formed in June 2004 to develop a high content cell-based screening ... ''

Also think on this .... Apredica were paying Cellumen to carry out the actual high throughput screening on Cellumen own machines using Cellumen developed technology and Cellumen owned intellectual property (IP). The scientists at Apredica ..... 5 of at that time .... were formulating new assays ie doing the clever stuff , whilst Cellumen technicians were doing the grunt work so to speak.

Now Cyprotex own the lot .... so no payments to Cellumen any more by Apredica ... all monies from the 3 companies come to Cyprotex AND THE WORK is now carried out by less staff as Cellumen staff have ceased to be.

[buywell2] 01/11/2010 16:46

Can't see that ... but if he was he has got his work cut out with the former Apredica owners holding 25% of CRX stock and seats on the board.

It is in their and IPGL's interest (owns 12%) to get the share price of the company up so that at some point in the future ( next 3 years) Cyprotex gets sold for a decent price instead of peanuts.

[spekky] 01/11/2010 12:30

Can't help wondering if Mr Clothier may have been behind the previous attempt to buy CRX on the cheap.

[old crow] 01/11/2010 12:09

Another 83K buy @ 4.75p for the Crow ignore the ? it's the Crows buy.

[old crow] 01/11/2010 09:41

buywell, keep it flowing.

[buywell2] 01/11/2010 07:51

Sooner we get an update out the better

I think we should have put one out weeks back

If the news is good the share would not have fallen back and momentum lost

[buywell2] 01/11/2010 07:50

Makes sense .... if he gets a vote on the BOD

Anybody know if he does ?

1 November 2010

Cyprotex PLC
("Cyprotex" or the "Company")

Appointment of New Non-Executive Director


Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, today
announces the appointment of Christopher Gurth Clothier as Non-Executive
Director, effective as of 1st November 2010. Mr Clothier will serve on the
Audit and Remuneration Committees of the Company.

Mr Clothier, aged 31, is currently Investment Director at IPGL Limited, the
Company's second largest shareholder, with a holding of 27, 024,465 ordinary
shares representing 12.08% of the issued share capital of the Company. Mr
Clothier has previously been Investment Director at MMC Ventures, and a
consultant with Roland Berger Strategy Consultants GmbH. Mr Clothier received
his MChem from New College, University of Oxford, in 2002.

Mr Steve Harris, Non-Executive Chairman of Cyprotex, said: "We are delighted to
welcome Chris Clothier to our Board as Non-Executive Director. Chris brings a
wealth of knowledge of the Company and will have invaluable strategic input into
the business going forward. The Company's three largest shareholders are now
represented on the Board, whose interests are fully aligned with those of the
rest of our shareholders."

Mr Chris Clothier added: "I am delighted to be joining Cyprotex at such an
exciting time for the business. The recent acquisition of US-based Apredica has
substantially enhanced the Company's presence in the US, and has accelerated its
entry into the fast-growing in vitro toxicology market, both of which represent
significant growth opportunities. As a representative of Cyprotex's
second-largest shareholder, I am personally committed to helping the Company
enhance shareholder value."

[cotton4] 01/11/2010 07:23

Like this bit

The recent acquisition of US-based Apredica has substantially enhanced the Company's presence in the US, and has accelerated its entry into the fast-growing in vitro toxicology market, both of which represent significant growth opportunities

Past tense

[cotton4] 01/11/2010 07:04

Appointment of New Non-Executive Director



TIDMCRX

RNS Number : 3205V
Cyprotex PLC
01 November 2010